2021 MIPS Measure #146: Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Screening Mammograms 

Measure Type High Priority Measure? Collection Type(s)
Process yes Medicare Part B Claims, MIPS CQM

 

Measure Description

Percentage of final reports for screening mammograms that are classified as “probably benign”

Instructions

This measure is to be submitted each time a screening mammogram is performed during the performance period. It is anticipated that eligible clinicians who provide the professional component of diagnostic imaging studies for screening mammograms will submit this measure.

Measure Submission Type:

Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

Denominator

All final reports for screening mammograms

Denominator Criteria (Eligible Cases):

Diagnosis for screening mammogram (ICD-10-CM): Z12.31

AND

Patient procedure during the performance period (CPT or HCPCS): 77067

Numerator

Final reports classified as “probably benign”

Numerator Instructions:

INVERSE MEASURE – A lower calculated performance rate for this measure indicates better clinical care or control. The “Performance Not Met” numerator option for this measure is the representation of the better clinical quality or control. Submitting that numerator option will produce a performance rate that trends closer to 0%, as quality increases. For inverse measures, a rate of 100% means all of the denominator eligible patients did not receive the appropriate care or were not in proper control.

A lower percentage, with a definitional target approaching 0%, indicates appropriate assessment of screening mammograms.

The mammogram assessment category (corresponding CPT Category II 33xxF code for assessment categories”) to be submitted is the final assessment for the screening mammographic study. If a diagnostic mammographic study follows the screening exam, the assessment category for the screening exam should be submitted with the corresponding CPT Category II code, i.e. 3340F for Mammogram assessment category of

“incomplete: need additional imaging evaluation,” documented. Of note, the performance tags indicating

‘Performance Met’ and ‘Performance Not Met’ are included to highlight what is being measured and submitted and not to encourage the use and documentation of “probably benign”.

Definition:

“Probably Benign” Classification – Mammography Quality Standards Act (MQSA) assessment category of “probably benign”; Breast Imaging-Reporting and Data System (BI-RADS®) category 3; or Food and Drug Administration (FDA)-approved equivalent assessment category

Numerator Options: 

Performance Met:

Mammogram assessment category of “probably benign,” documented (3343F)

OR

Performance Not Met:

Mammogram assessment category of “incomplete: need additional imaging evaluation,” documented (3340F)

OR

Performance Not Met:

Mammogram assessment category of “negative,” Documented (3341F)

OR

Performance Not Met:

Mammogram assessment category of “benign,” Documented (3342F)

OR

Performance Not Met:

Mammogram assessment category of “suspicious,” Documented (3344F)

Performance Not Met:

Mammogram assessment category “highly suggestive of malignancy,” documented (3345F)

OR

Performance Not Met:

Mammogram assessment category of “known biopsy proven malignancy,” documented (3350F)


Tags

CMS-Diagnostic-Radiology-2021, Diagnostic Radiology, Nuclear Medicine-2021, Quality-2021, Radiation Oncology-2021, Radiology-2021